This company has been marked as potentially delisted and may not be actively trading. Mirati Therapeutics (MRTX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock MRTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Mirati Therapeutics Stock Price HistoryMay 26, 2025 | investing.comMirati Therapeutics (NASDAQ:MRTX) Earns Sell Rating from Analysts at StockNews.comJanuary 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Boosts Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)January 25, 2024 | marketbeat.comMirati Therapeutics (Nasdaq:MRTX) HeadlineTrading was temporarily halted for "MRTX" at 07:01 PM with a stated reason of "News pending."...January 23, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Benjamin Hickey Sells 1,597 SharesJanuary 18, 2024 | marketbeat.comTD Asset Management Inc Grows Position in Mirati Therapeutics, Inc. (NASDAQ:MRTX)January 16, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Sees Large Decline in Short InterestJanuary 12, 2024 | marketbeat.comMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | markets.businessinsider.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJanuary 10, 2024 | finance.yahoo.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Receives Average Recommendation of "Hold" from AnalystsJanuary 10, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells $123,142.80 in StockJanuary 9, 2024 | marketbeat.comInsider Selling: Mirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells 1,531 Shares of StockJanuary 5, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Stock Position Reduced by Handelsbanken Fonder ABJanuary 5, 2024 | marketbeat.comSG Americas Securities LLC Buys 25,335 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)December 28, 2023 | marketbeat.comEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 25, 2023 | seekingalpha.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | reuters.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 22, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | msn.comMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesDecember 20, 2023 | finance.yahoo.comMirati Therapeutics (NASDAQ:MRTX) Stock Rating Reaffirmed by CitigroupDecember 20, 2023 | marketbeat.comInsider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)December 15, 2023 | finance.yahoo.comMirati Therapeutics Inc MRTXDecember 12, 2023 | morningstar.comMBillionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading ChargesDecember 12, 2023 | finance.yahoo.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Sold by Braidwell LPDecember 11, 2023 | marketbeat.comCamber Capital Management LP Buys 400,000 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)December 10, 2023 | marketbeat.comCasdin Capital LLC Reduces Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)December 8, 2023 | marketbeat.comMirati Therapeutics Stock (NASDAQ:MRTX), Short Interest ReportDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX) Dividends: History, Yield and DatesDecember 3, 2023 | benzinga.comMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law FirmNovember 15, 2023 | benzinga.comMirati Therapeutics Gets CHMP Backing for KrazatiNovember 10, 2023 | marketwatch.comMirati's lung cancer drug gets EU's regulatory backingNovember 10, 2023 | reuters.comUPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingNovember 10, 2023 | finance.yahoo.comLeerink Partners Downgrades Mirati Therapeutics (MRTX)November 8, 2023 | msn.comStifel Downgrades Mirati Therapeutics (MRTX)November 8, 2023 | msn.comParamount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cutsNovember 7, 2023 | finance.yahoo.comMirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 6, 2023 | finance.yahoo.comMirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer PatientsNovember 3, 2023 | marketwatch.comKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNovember 2, 2023 | finance.yahoo.comMirati Therapeutics (MRTX) Price Target Increased by 16.97% to 64.71November 1, 2023 | msn.comMirati Therapeutics Inc (26M.BE)October 26, 2023 | finance.yahoo.comHold Rating on Mirati Therapeutics: A Comparative Analysis with Amgen and Future ProspectsOctober 18, 2023 | markets.businessinsider.comPiper Sandler Downgrades Mirati Therapeutics (MRTX)October 12, 2023 | msn.comMirati Therapeutics Falls 5% After Bristol Myers Squibb Decides To Acquire ItOctober 11, 2023 | markets.businessinsider.comMirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8BOctober 11, 2023 | finance.yahoo.comMirati Therapeutics: Anatomy Of A Long Simmering BuyoutOctober 10, 2023 | msn.comMIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati ...October 9, 2023 | businesswire.comMirati Therapeutics could see another bidder emerge, Leerink saysOctober 9, 2023 | msn.comShareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers SquibbOctober 9, 2023 | benzinga.comMRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to ShareholdersOctober 8, 2023 | businesswire.com Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Media Mentions By Week MRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRTX News Sentiment▼0.000.75▲Average Medical News Sentiment MRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRTX Articles This Week▼00▲MRTX Articles Average Week Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MOR News Today CALT News Today ZYME News Today MBX News Today AVTE News Today CYBN News Today VIRI News Today PYRGF News Today ELYM News Today ATNM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRTX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirati Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access